Skip to main content


Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) may have an increased risk of a subsequent psychotic disorder (PD), according to a meta-analysis recently published online in JAMA Psychiatry.
The US Food and Drug Administration has classified the resubmission of the New Drug Application for SPN-812 as Class I, setting early April as the Prescription Drug User Fee Act target action date, Supernus Pharmaceuticals, Inc. announced.
Task-based functional connectivity can serve as a biomarker for attention-deficit/hyperactivity disorder (ADHD), according to a study published online in Frontiers in Physiology.
Supernus Pharmaceuticals, Inc. has resubmitted a New Drug Application (NDA) to the US Food and Drug Administration for approval of SPN-812 for pediatric attention deficit/hyperactivity disorder (ADHD).
An investigational extended-release amphetamine tablet met its primary efficacy endpoint—sustained attention in adults with attention-deficit/hyperactivity disorder (ADHD)—in a phase 3 trial, Tris Pharma Inc. recently announced.
Back to Top